title: The CYP2D6 genotype and plasma concentrations of mianserin enantiomers in relation to therapeutic response to mianserin in depressed Japanese patients.
abstract: The relationship between therapeutic response to racemic mianserin and steady-state plasma concentrations of S(+)- and R(-)-mianserin was studied in 26 Japanese patients with major depression. The daily dose of mianserin was 30 mg, and the duration of treatment was 3 weeks. Regarding S-mianserin, the proportion of responders (final Montgomery-Asberg Depression Rating Scale score of 10 or less) was significantly higher in the plasma concentration range of 10 to 23 ng/mL than outside (10 of 11 vs. 3 of 15, p = 0.0005). Such a plasma concentration difference between responders and nonresponders was not found for R-mianserin. In 15 patients, the relationships between the CYP2D6 genotype, determined by allele-specific polymerase chain reaction analysis and Escherichia coli RI restriction fragment length polymorphism, plasma concentrations of the enantiomers, and the therapeutic response were studied. Five patients were homozygous for the wild type (wt) allele (wt/wt), nine were heterozygous for the CYP2D6Ch (Ch) allele causing decreased CYP2D6 activity (Ch/wt), and one patient was heterozygous for the Ch allele and the defect allele CYP2D6D (D) (Ch/D). The Ch/wt group showed significantly higher plasma concentrations of S-mianserin (mean +/- SD: 15 +/- 6 vs. 8 +/- 1 ng/mL, p = 0.007) and proportion of responders (8 of 9 vs. 1 of 5, p = 0.023) than the wt/wt group. The patient with the Ch/D genotype had the highest plasma concentration of S-mianserin (37 ng/mL) and a poor response. No significant relationship was found between the CYP2D6 genotype and plasma concentration of R-mianserin. The study presented here thus suggests that the CYP2D6 genotype plays a major role in controlling plasma concentration of the S-enantiomer of mianserin, which contributes to a major extent to the antidepressant effect during mianserin treatment.
authors.affiliation: Department of Neuropsychiatry, Hirosaki University Hospital, Japan.
authors.forename: K
authors.initials: K
authors.lastname: Mihara
authors.forename: K
authors.initials: K
authors.lastname: Otani
authors.forename: G
authors.initials: G
authors.lastname: Tybring
authors.forename: M L
authors.initials: ML
authors.lastname: Dahl
authors.forename: L
authors.initials: L
authors.lastname: Bertilsson
authors.forename: S
authors.initials: S
authors.lastname: Kaneko
mesh_terms: D000328:Adult; D018687:Antidepressive Agents, Second-Generation / Q000097:blood* / Q000627:therapeutic use*; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics / Q000378:metabolism*; D003866:Depressive Disorder / Q000188:drug therapy*; D005260:Female; D005838:Genotype; D006801:Humans; D007564:Japan; D008297:Male; D008803:Mianserin / Q000097:blood* / Q000627:therapeutic use*; D008875:Middle Aged; D013237:Stereoisomerism
chemical_list: D018687:Antidepressive Agents, Second-Generation; D008803:Mianserin; D019389:Cytochrome P-450 CYP2D6